Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Rivastigmine hydrogen tartrate 0.8 mg, 1.6 mg, 2.4 mg, 4.8 mg, 7.2 mg and 9.6 mg equivalent to 0.5 mg, 1 mg, 1.5 mg, 3 mg, 4.5 mg and 6 mg rivastigmine base Capsules Novartis Pharma AG., Basle, Switzerland Exelon Note: This consent is valid for 2 years from the date of publication of this notice. Dated this 4th day of November 1997. G. R. BOYD, Chief Adviser, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.